Intellizon

Based in Suzhou, China and founded in 2024, Intellizon Medical Ltd. , dba Intellizon, is a medical technology company focusing on the research, development and application of brain-computer interface technologies in treating brain diseases. In May 2026, Intellizon raised approximately CNY 100 million in pre-series A funding co-led by Nuoyu Capital and Well Lead Medical with participation from Chuchang Fund, Xiangshuo Equity Investment, Proxima Ventures and Suzhou Angel Investment Guidance Fund. Intellizon is engaged in both invasive and non-invasive brain-computer interface technologies in treating brain diseases.

The company's main focus is the development of "Brain-Spinal Interface", a product that collects brain movement intention signals, bypasses the damaged area, and directly stimulates the spinal cord nerves, aiming to assist paralyzed patients in regaining their ability to stand and walk. The company also develops multiple medical devices in three areas: motor disorders, mental illnesses, and neurodegenerative diseases and injuries in the elderly, targeting patients suffering from conditions such as spinal cord injuries, pain, depression, stroke, tremors, and incontinence. The company's revenue is generated from sales of its medical devices to healthcare institutions and partners. The company will use the pre-series A funding to advance the implementation of its implantable bidirectional brain-computer interface full-stack technology; accelerate the mass production and clinical progress of "brain-spinous interface" application scenarios; comprehensively explore various application scenarios based on its brain-computer interface technology platform; and continuously empower the commercialization of its certified and marketed products.